Metastatic Pancreatic Cancer Clinical Trial

Trial Summary

A Phase 1/2 Open-Label, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer.

More Information on this Clinical Trial

Frequently Asked Questions

A Clinical Trial is a type of research study that examines how well a potential therapy works in humans.

Phase 1 of this will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metastatic pancreatic cancer. Phase 2a study will be conducted after completion of the Phase 1 portion using a two-stage, open-label design, of RX 3117 and Abraxane® in combination to treat subjects with metastatic pancreatic cancer as first line therapy.

This clinical trial has certain criteria that a person has to meet to determine if they can participate. After you have discussed the trial with your doctor, specific tests will be done to see if you qualify for this study.

Rexahn Pharmaceuticals, Inc. is sponsoring this clinical trial.

There will be a total of 50 patients enrolled in this clinical trial.

Have your physician complete the contact form.